{"id":42175,"date":"2025-09-24T13:59:31","date_gmt":"2025-09-24T05:59:31","guid":{"rendered":"https:\/\/flcube.com\/?p=42175"},"modified":"2025-09-24T13:59:32","modified_gmt":"2025-09-24T05:59:32","slug":"sino-biopharmaceutical-reports-first%e2%80%91patient-enrollment-for-lm%e2%80%912417-phase-i-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42175","title":{"rendered":"Sino Biopharmaceutical Reports First\u2011Patient Enrollment for LM\u20112417 Phase\u202fI Trial"},"content":{"rendered":"\n

China\u2011based Sino Biopharmaceutical (HKG: 1177<\/a>)<\/strong> announced today that its internally\u2011developed Class\u202f1 innovative drug LM\u20112417<\/strong> has successfully enrolled its first patient in a Phase\u202fI clinical trial in China. The milestone marks a critical step toward evaluating the safety and pharmacodynamics of this novel bispecific antibody in patients with advanced solid tumours.<\/p>\n\n\n\n

What Is LM\u20112417?<\/h2>\n\n\n\n

LM\u20112417 is a NaPi2b\/4\u20111BB bispecific antibody<\/strong> engineered by LaNova Medicine<\/strong> on a proprietary conditionally\u2011activated 4\u20111BB platform. The dual\u2011specificity design allows the antibody to simultaneously bind the tumour\u2011specific NaPi2b antigen and the immune\u2011cell co\u2011stimulatory receptor 4\u20111BB. By localising immune activation to the tumour microenvironment, LM\u20112417 aims to amplify antitumour immunity while limiting systemic toxicity.<\/p>\n\n\n\n

Phase\u202fI Trial Design<\/h2>\n\n\n\n

The first\u2011in\u2011human study will enroll patients with refractory or metastatic solid tumours that express NaPi2b. Participants will receive escalating doses of LM\u20112417 to determine the maximum tolerated dose, dose\u2011limiting toxicities, and pharmacokinetic profile. The trial will also collect tumour biopsies and peripheral blood samples to assess immune activation markers and early efficacy signals.<\/p>\n\n\n\n

Strategic Significance<\/h2>\n\n\n\n